Unspecified type of carcinoma in situ of breast
ICD-10 D05.9 is a billable code used to indicate a diagnosis of unspecified type of carcinoma in situ of breast.
Carcinoma in situ (CIS) of the breast refers to a group of abnormal cells that are found in the lining of the breast ducts or lobules. These cells have the potential to become invasive cancer but are currently confined to their original location. The term 'unspecified type' indicates that the specific subtype of carcinoma in situ, such as ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), has not been determined. Patients diagnosed with D05.9 may undergo various surveillance protocols, including regular mammograms and clinical breast exams, to monitor for any signs of progression to invasive cancer. The risk of progression varies based on factors such as the size of the lesion, histological features, and patient age. While many patients with DCIS may not progress to invasive disease, those with LCIS have a higher risk of developing breast cancer in either breast over time. Therefore, individualized risk assessment and management strategies are essential for optimal patient outcomes.
Detailed pathology reports, treatment plans, and follow-up care notes.
Diagnosis of carcinoma in situ, treatment planning, and monitoring for progression.
Ensure accurate documentation of tumor characteristics and patient risk factors.
Imaging reports, findings from mammograms, and breast ultrasounds.
Screening mammograms showing suspicious findings, follow-up imaging for known carcinoma in situ.
Clear documentation of imaging findings and recommendations for further evaluation.
Used when a patient with D05.9 undergoes surgical intervention for carcinoma in situ.
Operative report detailing the procedure and findings.
Oncologists should ensure that the diagnosis is clearly linked to the surgical procedure.
Carcinoma in situ refers to abnormal cells that are localized and have not invaded surrounding tissues. It is considered a non-invasive form of cancer.
Treatment options may include surgery, radiation therapy, and hormone therapy, depending on the specific type and individual patient factors.
The risk of progression to invasive cancer varies based on the type of carcinoma in situ, with DCIS having a lower risk compared to LCIS, which increases the risk of developing breast cancer in either breast.
